Sentence examples for progression the trial from inspiring English sources

In case of a rapid tumour progression, the trial was terminated (usually 39 60 days) and the general condition of the animals (defined in terms of the condition of the coat, nutrition and behaviour) was assessed daily.

The baseline sphere also was correlated significantly with the RPRE in the nasal and temporal retina and the amount of baseline sphere was correlated with the amount of progression before the trial, which agreed with the outcome that the nasal retina seems to be related more to myopic progression [ 25] and relative peripheral hyperopia associated with the amount of central myopia [ 26].

Kulik et al. reported the occurrence of disease progression during the trial in one patient under Sorafenib and one patient of the control group [ 40].

The annual rate of progression during the trial was calculated as the change in observed (at week 104) or linearly extrapolated (at week 208) mSASSS score from baseline divided by the elapsed time in the trial.

Finally, information on participant disposition was collected to document the recruitment of participants and their progression through the trial, numbers receiving intended treatment, those completing the study protocol and analysed for the primary outcome [ 14, 24].

In the second line setting, cetuximab/irintoecan significantly improved ORR and PFS (Sobrero et al, 2008), but with the commercial availability of cetuximab to patients in the irinotecan control arm on disease progression during the trial, no benefits were seen with OS, although other factors might have contributed to the lack of OS improvement.

Transition across these health states will be based on probabilities in relation to long-term treatment effects, safety and disease progression derived from the trial findings and/or literature review.

Figure 1 shows the progression of participants through the trial.

Figure  7 shows the trial progression for one subject when tracking the 80% compressed point.

All patients presented with either clinical or radiologically documented progression at entry into the trial.

This limitation of our study may be due to the fact that the patients did not require a proven keratometric progression for enrolment in the trial.